| Antiviral | EC50 ratio | Phenotype | Strain | Source | Marker | Assay | Reference |
|---|---|---|---|---|---|---|---|
| Maribavir | 17.00 | High level resistance | Laboratory strain, Clinical Isolate | Recombinant | Details | Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024) | |
| Ganciclovir | 0.50 | No resistance | Laboratory strain, Clinical Isolate | Recombinant | Details | Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024) | |
| Maribavir | 15.00 | High level resistance | Laboratory strain, Clinical Isolate | Details | Drug Resistance Mutations and Associated Phenotypes Detected in Clinical Trials of Maribavir for Treatment of Cytomegalovirus Infection. (Sep 2022) |
| Mutant | Resistances |
|---|---|
| H411L |
Maribavir:
|
| H411L |
Ganciclovir:
|
| H411N |
Maribavir:
|
| H411N |
Ganciclovir:
|